[go: up one dir, main page]

DK3500572T3 - Cytisinderivater til behandling af afhængighed - Google Patents

Cytisinderivater til behandling af afhængighed Download PDF

Info

Publication number
DK3500572T3
DK3500572T3 DK17771833.5T DK17771833T DK3500572T3 DK 3500572 T3 DK3500572 T3 DK 3500572T3 DK 17771833 T DK17771833 T DK 17771833T DK 3500572 T3 DK3500572 T3 DK 3500572T3
Authority
DK
Denmark
Prior art keywords
cytisis
addiction
derivatives
treatment
cytisis derivatives
Prior art date
Application number
DK17771833.5T
Other languages
English (en)
Inventor
Timothy Charles Gallagher
Campello Hugo Rego
Original Assignee
Univ Bristol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1614235.8A external-priority patent/GB201614235D0/en
Priority claimed from GBGB1709642.1A external-priority patent/GB201709642D0/en
Application filed by Univ Bristol filed Critical Univ Bristol
Application granted granted Critical
Publication of DK3500572T3 publication Critical patent/DK3500572T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/18Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms
    • B01J31/1805Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms the ligands containing nitrogen
    • B01J31/181Cyclic ligands, including e.g. non-condensed polycyclic ligands, comprising at least one complexing nitrogen atom as ring member, e.g. pyridine
    • B01J31/1815Cyclic ligands, including e.g. non-condensed polycyclic ligands, comprising at least one complexing nitrogen atom as ring member, e.g. pyridine with more than one complexing nitrogen atom, e.g. bipyridyl, 2-aminopyridine
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/18Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms
    • B01J31/1805Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms the ligands containing nitrogen
    • B01J31/181Cyclic ligands, including e.g. non-condensed polycyclic ligands, comprising at least one complexing nitrogen atom as ring member, e.g. pyridine
    • B01J31/1825Ligands comprising condensed ring systems, e.g. acridine, carbazole
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • B01J31/2409Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring with more than one complexing phosphine-P atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK17771833.5T 2016-08-19 2017-08-17 Cytisinderivater til behandling af afhængighed DK3500572T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1614235.8A GB201614235D0 (en) 2016-08-19 2016-08-19 Compounds
GBGB1709642.1A GB201709642D0 (en) 2017-06-16 2017-06-16 Compounds
PCT/GB2017/052438 WO2018033742A2 (en) 2016-08-19 2017-08-17 Compounds

Publications (1)

Publication Number Publication Date
DK3500572T3 true DK3500572T3 (da) 2022-12-19

Family

ID=59930645

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17771833.5T DK3500572T3 (da) 2016-08-19 2017-08-17 Cytisinderivater til behandling af afhængighed

Country Status (15)

Country Link
US (3) US11667638B2 (da)
EP (2) EP4112620A1 (da)
JP (3) JP7178538B2 (da)
CN (1) CN110088106A (da)
AU (4) AU2017313390A1 (da)
CA (1) CA3032899A1 (da)
DK (1) DK3500572T3 (da)
ES (1) ES2935204T3 (da)
GB (1) GB2558700B (da)
HR (1) HRP20221497T1 (da)
HU (1) HUE061016T2 (da)
LT (1) LT3500572T (da)
PL (1) PL3500572T3 (da)
RS (1) RS63872B1 (da)
WO (1) WO2018033742A2 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201602145D0 (en) 2016-02-05 2016-03-23 Achieve Pharma Uk Ltd Salt
DK3500572T3 (da) * 2016-08-19 2022-12-19 Univ Bristol Cytisinderivater til behandling af afhængighed
TW202404969A (zh) 2022-04-22 2024-02-01 美商維泰克斯製藥公司 用於治療疼痛之雜芳基化合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5242916A (en) * 1992-07-07 1993-09-07 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
WO1998018798A1 (en) 1996-10-30 1998-05-07 Pfizer Inc. Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy
US8030300B2 (en) * 2003-06-10 2011-10-04 Georgetown University Ligands for nicotinic acetylcholine receptors, and methods of making and using them
BG65536B1 (bg) 2004-04-16 2008-11-28 "Софарма" Ад Лекарствена форма, съдържаща цитизин
WO2007100430A2 (en) * 2006-01-27 2007-09-07 Yale University Cytisine and acetylcholine analogs and methods of treating mood disorders
US20100048606A1 (en) * 2006-03-29 2010-02-25 Georgetown University Office of Technology Commercialization 10-Substituted Cytisine Derivatives and Methods of Use Thereof
CN101534833B (zh) * 2006-07-18 2013-03-13 贝塞斯达药理学联合有限责任公司 烟碱脱敏剂及选择、测试及使用它们的方法
JO3078B1 (ar) 2009-11-27 2017-03-15 Janssen Pharmaceutica Nv مورفولينوثيازولات بصفتها منظمات الوستيرية نوع الفا 7 موجبة
TWI567061B (zh) 2011-07-01 2017-01-21 吉李德科學股份有限公司 用於治療成癮之化合物
CN103509021B (zh) 2012-06-21 2016-08-17 天津药明康德新药开发有限公司 金雀花碱衍生物及其制备方法和抗癌作用研究
FR2992315B1 (fr) * 2012-06-25 2014-08-08 Pf Medicament Derives utiles dans le traitement de maladies du systeme nerveux central
US20160199315A1 (en) 2013-08-23 2016-07-14 Hisamitsu Pharmaceutical Co., Inc. Adhesive patch
DK3500572T3 (da) 2016-08-19 2022-12-19 Univ Bristol Cytisinderivater til behandling af afhængighed

Also Published As

Publication number Publication date
JP7178538B2 (ja) 2022-11-28
CN110088106A (zh) 2019-08-02
LT3500572T (lt) 2023-02-10
EP4112620A1 (en) 2023-01-04
WO2018033742A3 (en) 2018-05-17
EP3500572A2 (en) 2019-06-26
AU2021261840B2 (en) 2023-08-03
GB2558700B (en) 2022-07-27
JP7668016B2 (ja) 2025-04-24
JP2019528286A (ja) 2019-10-10
JP2022159381A (ja) 2022-10-17
US11667638B2 (en) 2023-06-06
RS63872B1 (sr) 2023-02-28
WO2018033742A2 (en) 2018-02-22
AU2023248084A1 (en) 2023-11-02
ES2935204T3 (es) 2023-03-02
AU2017313390A1 (en) 2019-03-07
AU2023248084B2 (en) 2025-06-19
EP3500572B1 (en) 2022-10-26
US11905287B2 (en) 2024-02-20
US20240287073A1 (en) 2024-08-29
US20200172544A1 (en) 2020-06-04
HUE061016T2 (hu) 2023-05-28
CA3032899A1 (en) 2018-02-22
GB201713217D0 (en) 2017-10-04
AU2025223941A1 (en) 2025-09-18
US20230203038A1 (en) 2023-06-29
AU2021261840A1 (en) 2021-12-02
PL3500572T3 (pl) 2023-02-06
HRP20221497T1 (hr) 2023-02-17
JP2025028923A (ja) 2025-03-05
GB2558700A (en) 2018-07-18

Similar Documents

Publication Publication Date Title
DK3521282T3 (da) Quinazolinderivater anvendt til behandling af hiv
IL264143B (en) Processes for preparing olaparib
DK3192902T3 (da) Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3492632T3 (da) Metoder til behandling af lithiumholdige materialer
DK3556775T3 (da) Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter
DK3096741T3 (da) Fremgangsmåde til fremstillingen af hybridosomer
DK3466432T3 (da) Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner
DK3325443T3 (da) Fremgangsmåde til fremstilling af pridopidin
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3174858T3 (da) Fremgangsmåde til fremstilling af pyrazoler
DK3503890T3 (da) Anvendelse af pridopidin til behandling af dystonier
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3148529T3 (da) Forbindelser til behandling af hjernecancer
DK3157534T3 (da) Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande
DK3506904T3 (da) Behandling af demens
DK3134084T3 (da) Fremgangsmåde til behandling af lungeadenokarcinom
LT3402792T (lt) Chinolin-2-ono dariniai
DK3097085T3 (da) Benzoxazinonderivater til behandling af hudsygdomme
PT3457851T (pt) Derivados de sobetiroma
DK3164123T3 (da) Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
DK3318115T3 (da) Maskine til behandling af svinegylle
DK3280408T3 (da) Fremgangsmåde til fremstilling af dicycloplatin
DK3261661T3 (da) Menotropin til behandling af infertilitet
DK3468604T3 (da) Farmaceutiske kombinationer til behandling af cancer